PTHS
AMEXPelthos Therapeutics Inc.
News25/Ratings6
Price$26.86-0.16 (-0.59%)
2026-05-212026-08-25
News · 26 weeks54+125%
2026-03-012026-08-23
Mix1990d
- SEC Filings8(42%)
- Insider5(26%)
- Other3(16%)
- Earnings2(11%)
- Offering1(5%)
Latest news
25 items- SECSEC Form DEFA14A filed by Pelthos Therapeutics Inc.DEFA14A - Pelthos Therapeutics Inc. (0001919246) (Filer)
- SECSEC Form DEF 14A filed by Pelthos Therapeutics Inc.DEF 14A - Pelthos Therapeutics Inc. (0001919246) (Filer)
- SECSEC Form 10-Q filed by Pelthos Therapeutics Inc.10-Q - Pelthos Therapeutics Inc. (0001919246) (Filer)
- SECPelthos Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Pelthos Therapeutics Inc. (0001919246) (Filer)
- PRPelthos Therapeutics Announces Second Quarter 2026 Financial ResultsZelsuvmi® net product revenue grew 45% to $15.4 million during the second quarter of 2026 from $10.7 million in the first quarter of 2026 11,925 Zelsuvmi units were dispensed by 4,571 unique prescribers during the second quarter of 2026, representing a 48% quarter-over-quarter increase in units dispensed More than 25,000 patients have now been prescribed Zelsuvmi since it was commercially launched in July 2025 Management will host a conference call today, August 13, 2026, at 8:30 a.m. ET DURHAM, N.C., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patie
- SECAmendment: SEC Form 10-Q/A filed by Pelthos Therapeutics Inc.10-Q/A - Pelthos Therapeutics Inc. (0001919246) (Filer)
- SECPelthos Therapeutics Inc. filed SEC Form 8-K: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review8-K - Pelthos Therapeutics Inc. (0001919246) (Filer)
- SECSEC Form PRE 14A filed by Pelthos Therapeutics Inc.PRE 14A - Pelthos Therapeutics Inc. (0001919246) (Filer)
- PRPelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026DURHAM, N.C., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"), today announced it will report second quarter 2026 financial results on Thursday, August 13, 2026. The company will hold a conference call followed by a question-and-answer period at 8:30 a.m. Eastern Time. Details for the conference call can be found below: Date:Thursday, August 13, 2026Time:8:30 a.m. Eastern TimeToll Free:1-877-451-6152International:1-201-389-0879Conf.ID:13761132 Call.Me: Participants can use the dial-in numbers above or click the CallMe link for instant tele
- PRPelthos Therapeutics Announces 2026 Annual Meeting of StockholdersDURHAM, N.C., July 24, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS) (the "Company" or "Pelthos") today announced that it will hold its 2026 Annual Meeting of Stockholders virtually on Tuesday, September 29, 2026 at 9:00 a.m. Eastern Time. Stockholders of record as of the close of business on August 4, 2026 are entitled to notice of and to vote at the 2026 Annual Meeting. The Company anticipates filing the Notice of Annual Meeting and proxy statement in early August 2026. The date of the 2026 Annual Meeting represents a change of more than 30 days from the anniversary of the Company’s 2025 Annual Meeting. Given the adjustment, stockholder proposals pursuant to Rule 14a-8
- INSIDERDirector Friedberg Ezra M sold $14,556 worth of shares (558 units at $26.09) as part of a pre-agreed trading plan, decreasing direct ownership by 0.68% to 81,042 units (SEC Form 4) to cover withholding tax4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)
- INSIDERDirector Pauls Matthew sold $20,561 worth of shares (786 units at $26.16) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 14,364 units (SEC Form 4) to satisfy withholding tax4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)
- INSIDERDirector Greenleaf Peter sold $20,827 worth of shares (797 units at $26.13) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 23,884 units (SEC Form 4) to satisfy withholding tax4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)
- PRPelthos Therapeutics Added to Russell 3000E™ Growth Benchmark, Russell Microcap® and Russell Microcap® Growth Benchmark IndexesDURHAM, N.C., June 30, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs, ("Pelthos"), today announced that the company was added as a member of the Russell 3000E™ Growth Benchmark, Russell Microcap®, and Russell Microcap® Growth Benchmark Indexes effective when the US market opened on June 29 as part of the 2026 Russell indexes reconstitution. The June Russell US Indexes reconstitution captures up to the 4,000 largest US stocks as of Thursday, April 30th, ranking them by total market capitalization. Beginning in 2026, the Russell US Indexes are reconstituted on a
- PRPalvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of DirectorsBrings more than 25 years of experience advancing and commercializing high-impact therapies for serious diseases, including those with limited or no approved treatment options Extensive public company and rare disease experience, including executive and Board roles at Savara Inc. (NASDAQ:SVRA), Soleno Therapeutics (NASDAQ:SLNO), Strongbridge Biopharma (NASDAQ:SBBP) and Insmed Incorporated (NASDAQ:INSM) WAYNE, Pa., June 30, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the "Company") (NASDAQ:PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which th
- INSIDERDirector Friedberg Ezra M sold $7,724 worth of shares (283 units at $27.29) as part of a pre-agreed trading plan, decreasing direct ownership by 0.35% to 81,600 units (SEC Form 4) to satisfy tax liability4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)
- INSIDERDirector Davis Todd C bought $999,983 worth of shares (35,948 units at $27.82), increasing direct ownership by 90% to 75,834 units (SEC Form 4)4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)
- SECPelthos Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Pelthos Therapeutics Inc. (0001919246) (Filer)
- PRPelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare ConferenceDURHAM, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs, ("Pelthos"), today announced that CEO Scott Plesha will present at 11:05 am ET and participate in one-on-one investor meetings at the Jefferies Global Healthcare Conference on June 4, 2026 in New York. Investors interested in arranging one-on-one meetings should contact their Jefferies representative. About Pelthos Therapeutics Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on building and advancing a portfolio of differentiated cutaneous infectious disease prod
- INSIDERCFO, Treas & Secty Francis Knuettel Ii returned 13,947 shares to the company and sold $40,265 worth of shares (1,500 units at $26.84), decreasing direct ownership by 42% to 19,525 units (SEC Form 4)4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)
- SECSEC Form 144 filed by Pelthos Therapeutics Inc.144 - Pelthos Therapeutics Inc. (0001919246) (Subject)
- SECPelthos Therapeutics Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Leadership Update, Financial Statements and Exhibits8-K - Pelthos Therapeutics Inc. (0001919246) (Filer)
- INSIDERDirector Friedberg Ezra M covered exercise/tax liability with 144 shares, decreasing direct ownership by 0.18% to 81,883 units (SEC Form 4) (withholding obligation)4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Pelthos Therapeutics Inc.SCHEDULE 13G/A - Pelthos Therapeutics Inc. (0001919246) (Subject)
- SECPelthos Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Pelthos Therapeutics Inc. (0001919246) (Filer)
PTHS FAQ
6 questionsWhere does PTHS stock trade?
Pelthos Therapeutics Inc. (PTHS) is listed on AMEX.What sector and industry is PTHS in?
Pelthos Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Pelthos Therapeutics Inc. go public?
Pelthos Therapeutics Inc. (PTHS) completed its IPO in 2024.What are analysts saying about PTHS?
Pelthos Therapeutics Inc. has had 6 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight on 2026-04-01. Recent price targets cluster around $4800.00.What companies are similar to PTHS?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare PTHS side-by-side with any of them on Quantisnow.How can I track PTHS on Quantisnow?
Quantisnow aggregates Pelthos Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PTHS to receive live email and push alerts on every new disclosure.